1. Introduction {#sec1}
===============

Malaysia has a multiracial population of 28.3 million, consisting of 65.1% Malays and other Bumiputera groups: 26% Chinese, 7.7% Indians, and 1.2% of other ethnic groups (Population and Housing Census, 2000). The "Orang Asli" or the indigenous population in Malaysia are descendents of the Austronesian people and they form only 0.6% of the total population \[[@B1]\]. In West Malaysia, they have been officially classified into three main categories---Proto-Malay (Aboriginal-Malay), Negrito and, Senoi \[[@B1]\]. East Malaysia has the largest number of indigenous groups which make up to 60% of Sabah\'s and 50% of Sarawak\'s population. The indigenous groups have mainly lived as agricultural and fishing communities, but many have now integrated into urban communities and hold important administrative and academic positions.

The thalassemias are autosomal recessive disorders which result in reduced production of one or more of the subunits of hemoglobin. Thalassemia is a public health problem in Malaysia and about 4.5% of the Malays and Chinese are *β*-thalassemia carriers \[[@B2]\]. Beta-thalassemia major produces severe anemia that requires life-long blood transfusions for survival. The molecular defects producing *β*-thalassemia are heterogeneous, and each ethnic group possesses its own specific set of mutations \[[@B3], [@B4]\]. Alpha-thalassemia has also been reported and the fatal condition, Hb Bart\'s hydrops fetalis, is present mainly in the Malaysian Chinese. The Malays possess the single *α*-globin gene deletion that produces an asymptomatic disorder \[[@B5]\]. Thalassemia has rarely been observed in the Malaysian Indians who are migrants mainly from Southern India.

Although thalassemia is the most common genetic disorder in Malaysia, there is very little information regarding the presence of thalassemia in the indigenous population. A previous study showed that the Filipino *β*-thalassemia deletion which involves deletion of the entire *β*-globin gene was the only mutation in 20 *β*-thalassemia major families from the indigenous communities in Sabah, East Malaysia \[[@B6]\]. Detailed molecular characterization of mutations that cause thalassemia in the Malaysian indigenous populations is limited, as studies have focused mainly on the major ethnic groups---Malays, Chinese and Indians. The aim of this molecular study is to detect the prevalence and types of *α*- and *β*-thalassemia in the Kadazandusuns, the largest indigenous group in Sabah. Information on the prevalence and spectrum of thalassemia defects will allow for effective genetic counseling and prenatal diagnosis of thalassemia in the Kadazandusuns in Sabah.

2. Materials and Methods {#sec2}
========================

A total of 125 blood samples were obtained with informed consent from unrelated Kadazandusuns in Sabah in 2008. Genomic DNA was obtained using conventional phenol-chloroform extraction. Routine hematology analysis including blood films for morphology was not done on the blood samples as they were collected from the interior and only reached the laboratory within 7 to 10 days of sample collection. In a recent study, we demonstrated that there was a progressive rise of the MCV from day 1 of storage \[[@B7]\]. High performance liquid chromatography (HPLC) to quantify hemoglobin subtypes in the blood samples for the presumptive diagnosis of thalassemia was also not possible as HPLC has to be carried out within 7 days of collection of blood samples stored at 4°C.

2.1. DNA Amplification of the *α*-Globin Gene {#sec2.1}
---------------------------------------------

Deletional *α*-thalassemia-Southeast Asian deletion (- -^SEA^); rightward −*α*^3.7^ and leftward −*α*^4.2^ deletions were confirmed using a modified multiplex PCR \[[@B8]\]. The Filipino (- -^FIL^) and Thai (- -^THAI^) *α*-thalassemia deletions were determined using separate assays \[[@B9]\]. The Filipino-specific deletion was amplified as a 597-bp fragment and the Thai-specific deletion as a 480-bp fragment. Amplification of the normal alleles for both deletions was simultaneously amplified in the same PCR reactions for each deletion. Amplification of the Mediterranean (- -^MED^) *α*-thalassemia deletion was not carried out in this study as this deletion has not been reported in Malaysia.

In addition, two nondeletional *α*-thalassemias, Hb Constant Spring (HbCS) and Hb Quong Sze (HbQS), reported in Malaysian Malays and Chinese were also determined using an in-house developed Combine-Amplification Refractory Mutation System \[[@B10]\]. All PCR products were electrophoresed on ethidium bromide-stained agarose gels followed by analysis.

2.2. Molecular Characterization of *β*-Thalassemia {#sec2.2}
--------------------------------------------------

To determine the presence of *β*-thalassemia in the Kadazandusuns, the Filipino *β*-thalassemia deletion was screened first as this mutation was observed in a fairly high frequency in the indigenous communities in Sabah \[[@B6], [@B11]\]. The primers, PCR mixture and PCR condition as described by Waye et al. \[[@B12]\], were used for the detection of the normal and the Filipino *β*-thalassemia deletion-specific sequence in this study.

Twenty-two common and rare *β*-globin gene mutations confirmed in Malaysians were determined in the Kadazandusuns using an in-house developed reverse dot blot system. The 22 mutations characterized are listed in [Table 1](#tab1){ref-type="table"}. The reverse dot blot used to characterize the *β*-globin gene defects was a modification of previously reported protocols \[[@B13], [@B14]\]. Briefly, specifically designed amino-modified oligonucleotide probes were applied to negatively-charged nylon membranes (Biodyne C Membrane, Pall USA). Beta-globin gene sequences in DNA from the Kadazandusuns were amplified in a multiplex PCR using DIG-labeled oligonucleotide primers. Amplified DNA was hybridized with the membrane strips at 42°C overnight. Membranes were washed with 0.5X SSC/0.1% SDS at 42°C for 30 minutes followed by a second wash with 2X SSC/0.1% SDS at room temperature, for 15 minutes. Detection was carried out using anti-Digoxigenin-Alkaline Phosphatase conjugate (Roche, Germany) followed by colour development using Nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate toluidine salt (Roche, Germany).

3. Results and Discussion {#sec3}
=========================

Results from the molecular characterization of *α*- and *β*-thalassemia are presented in [Table 1](#tab1){ref-type="table"}. Representative gel electrophoresis resulting from the Filipino *β*-thalassemia deletion in the *β*-globin gene is shown in [Figure 1](#fig1){ref-type="fig"}. The results from this preliminary study showed that 16/125 (12.8%) of the Kadazandusuns possessed the Filipino *β*-thalassemia deletion in the *β*-globin gene. This indicates a fairly high presence of *β*-thalassemia in the Kadazandusuns. The Filipino *β*-thalassemia deletion has been reported in a Filipino family, in two Australian families of Filipino descent, and in an Indonesian family of Malay descent \[[@B15]--[@B17]\]. The Filipino *β*-thalassemia deletion was first reported as a 45-kb deleted sequence in the *β*-globin gene \[[@B16]\]. However, subsequent investigations of the end points of the defect confirmed a 118.5-kb deleted sequence \[[@B12]\]. The deletion was also detected in 6/20 (30%) of mutant alleles in the Makasarese people from Celebes (East Indonesia) \[[@B18]\]. In another study of 2954 healthy Filipinos in Taiwan, the deletion was confirmed in 45.8% of the *β*-globin gene mutant alleles \[[@B19]\]. Filipino *β*-thalassemia deletion is not present in the Malaysian Malays and Chinese \[[@B11]\], and appears to be specific only to the indigenous communities in East Malaysia. Twenty-two other *β*-globin gene mutations previously reported in the Malaysian Malay, Chinese, and Indian racial groups were absent in the Kadazandusuns studied.

Alpha-thalassemia was also detected in the Kadazandusuns ([Figure 2](#fig2){ref-type="fig"}) as the single *α*-globin gene deletion (−*α*^3.7^) was confirmed in 33.6% (42/125) of the individuals. Heterozygosity for the deletion (−*α*^3.7^/*αα*) was confirmed in 27.2% (34/125) and homozygosity (−*α*^3.7^/−*α*^3.7^) in 6.4% (8/125) of the Kadazandusuns. The presence of the −*α*^3.7^ deletion is high in the Kadazandusuns when compared with the other racial groups. Previous studies showed that only 10.7% of Malaysian Malays, 10% of Chinese, and 7.4% of Indians possessed this deletion \[[@B5]\]. The single gene −*α*^3.7^ deletion has a worldwide distribution \[[@B20]\] and is most dominant in African, Mediterranean, and Asian populations \[[@B21]\]. The two nondeletional *α*-thalassemia studied, HbCS and HbQS, were absent in the 125 Kadazandusuns samples. In a previous study in another indigenous group, HbCS was reportedly present in the Dayaks in Sarawak \[[@B22]\]. The Filipino (- -^FIL^) and Thai (- -^THAI^) *α*-thalassemia deletions were absent in the Kadazandusuns. The Southeast Asian (- -^SEA^) *α*-thalassemia deletion reported in Malaysian Chinese and Malays was also absent in the Kadazandusuns. This confirms that thalassemia mutations are not only specific to different populations, but can also differ in frequency between racial and indigenous groups within the same population.

The indigenous population which comprise 40 ethnic groups make up about 60% of the estimated 2.6 million people in Sabah \[[@B23]\]. They speak more than 50 languages and 80 dialects, and occupy specific geographical areas. The indigenous population is thus not a homogenous group, as it differs in physical characteristics, languages, life styles, social organizations, and religions. The Kadazandusuns are the most dominant and largest group and are mainly farmers, but with progress in their social economic status, they are now also employed as administrators, traders and modern farmers.

Results from this study indicate that the 118.5-kb Filipino *β*-thalassemia deletion and the single *α*-globin gene deletion (−*α*^3.7^) are highly prevalent in the Kadazandusuns that inhabit the northern coastal plains and the mountain interiors of Sabah. Our sampling was from remote villages in Sonsogan Magandai, Sungai Magandai, Nalapak Pitas, and Panaitan. These are mainly impoverished villages that some are inaccessible by proper roads and do not have electricity or piped water supply. The health of the community is attended to by occasional flying doctors via helicopter service. Serious health problems are treated at the district hospitals and the individuals travel 5-6 hours by boats or public vehicles which cost 50--60 RM for a single journey. However, many resist seeking medical care as they are unable to pay for the transportation fare, because most families have unstable incomes and earn an average of 350 RM per month.

Carriers of *α*- and *β*-thalassemia are asymptomatic thus the affected individuals go through life unaware of their carrier status. Screening for thalassemia is not carried out on a routine basis on the Malaysian indigenous population. The Kadazandusuns frequently marry within their own group; thus, the risk of producing *β*-thalassemia major children is high since 12.8% of the Kadazandusuns studied possess Filipino *β*-thalassemia deletion.

In conclusion, the results from this study will serve as a baseline for further investigations into the genetic defects, and to provide better health services for the indigenous population in Malaysia. The DNA samples collected in this study were strictly selected from pure Kadazandusuns with no intermarriages with other ethnic groups for at least three generations. As the prevalence of both *α*- and *β*-thalassemia is relatively high in the Kadazandusuns, thalassemia screening should be quickly incorporated as a routine part of their healthcare system in order to identify asymptomatic carriers. The challenges to the implementation of more effective health care will include educating the Kadazandusuns about thalassemia as an inheritable disorder and, thus, the possibility of producing severely affected children. Genetic counseling and prenatal diagnosis have to be made available to husbands and wives who are carriers so that pregnancies with *β*-thalassemia major children are identified early and informed choices can be made with regards to continuation or termination of pregnancies. Management of children with *β*-thalassemia major should include availability of monthly blood transfusions and provision of iron chelation therapies to prevent death due to iron overload. Results and data derived from this study will be submitted to the Department for Orang Asli Affairs responsible for medical and health services for the indigenous populations in Malaysia. Specific programs relating to thalassemia screening and health care at the district hospitals for the indigenous populations will be proposed. Effective changes must be incorporated as the majority of the indigenous population in Malaysia are still unaware of their thalassemia status.
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![Detection of the Filipino *β*-thalassemia deletion on agarose gel after PCR. Lane 1: 100 bp molecular weight marker; lanes 2-3: normal controls with a 482-bp band; lanes 4--6: *β*-thalassemia carriers with the Filipino *β*-thalassemia deletion indicated by amplification of a 482 bp normal and a 376-bp deletion specific bands; lanes 7-8: *β*-thalassemia major with the Filipino *β*-thalassemia deletion indicated by amplification of a 376-bp band; lane 9: DNA blank.](JBB2010-706872.001){#fig1}

![*Detection of alpha-thalassemia on agarose gel after multiplex PCR.* Lane 1: DNA blank; lane 2: normal controls (*αα*/*αα*) with a 2350 bp LIS~1~ internal control band and a 1800 bp *α*2-globin gene band; lane 3: single *α*-globin gene deletion carrier (−*α*^3.7^/*αα*) with an internal control band, a 2022 bp deletion-specific band and an *α*2-globin gene band; lane 4: individual homozygous for *α*-globin gene deletion (−*α*^3.7^/−*α*^3.7^) with an internal control band and a 2022 bp deletion-specific band; lane 5 : 500 bp molecular weight marker.](JBB2010-706872.002){#fig2}

###### 

Frequency of *α*- and *β*-thalassemia defects in the Kadazandusuns in Sabah.

                  Deletional *α*-thalassemia   Nondeletional *α*-thalassemia   *β*-thalassemia                             
  --------------- ---------------------------- ------------------------------- ----------------- --- --- --- --- --------- ---
  Kadazandusun    42                           0                               0                 0   0   0   0   16        0
  *n* = 125 (%)   (33.6%)                                                                                        (12.8%)   

\*The 22 *β*-thalassemia mutations are CD41/42 (−CTTT), IVS2-654 (C→T), CD26 ([G]{.ul}AG→[A]{.ul}AG, HBE), IVS1-5 (G→C), −28 (A→G), CD43 ([G]{.ul}AG→[T]{.ul}AG), CD27/28 (+C), −29 (A→G), CD71/72 (+A), CD17 ([A]{.ul}AG→[T]{.ul}AG), CD19 (A[A]{.ul}C→A[G]{.ul}C), Poly A (AATA[A]{.ul}A→AATA[G]{.ul}A), −88 (C→T), Initiation codon (A[T]{.ul}G→A[G]{.ul}G), CAP (+1) (A→C), CD8/9 (+G), CD16 (−C), CD35 (−C), IVS2-1 (G→A), IVS1-1 (G→A), IVS1-1 (G→T) and CD15 (T[G]{.ul}G→T[A]{.ul}G).
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